Latest News

Latest News

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-Cell Engagers in Refractory Autoimmune Disease

Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...

read more
Medicine Does Not Run on Blood Alone

Medicine Does Not Run on Blood Alone

Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Safety, Toxicology, and Risk Assessment of Essential Oils

Safety, Toxicology, and Risk Assessment of Essential Oils

Essential oils are complex mixtures of volatile phytochemicals that have long been incorporated into traditional medicine, personal care products, aromatherapy, and topical therapeutic formulations. Their diverse biological activities—including antimicrobial,...

read more
Weekly News Roundup | 27 July 2026

Weekly News Roundup | 27 July 2026

Life science news 27 July 2026: GSK wins its first lung cancer approval with a selective ROS1 inhibitor, Lilly's triple agonist retatrutide delivers up to 22.6 per cent weight loss in two pivotal trials, and the MHRA clears what it calls the world's first lower-carbon...

read more
Clinical Trials Roundup | 24 July 2026

Clinical Trials Roundup | 24 July 2026

Merck's enlicitide receives FDA approval as the first oral PCSK9 inhibitor for adults with hypercholesterolaemia, GSK's zidesamtinib earns FDA approval as a next-generation ROS1 selective inhibitor for previously treated non-small cell lung cancer, GSK's camlipixant...

read more
The False Economy of Returning to Manual PGD Processes

The False Economy of Returning to Manual PGD Processes

Across healthcare, financial pressure is forcing difficult decisions. Pharmacy teams are being asked to do more with less. Service expansion, dealing with NHS patients, workforce shortages remain acute, and every investment is being scrutinised. In this environment,...

read more
Safety, Toxicology, and Risk Assessment of Essential Oils

Safety, Toxicology, and Risk Assessment of Essential Oils

Essential oils are complex mixtures of volatile phytochemicals that have long been incorporated into traditional medicine, personal care products, aromatherapy, and topical therapeutic formulations. Their diverse biological activities—including antimicrobial,...

read more
Weekly News Roundup | 27 July 2026

Weekly News Roundup | 27 July 2026

Life science news 27 July 2026: GSK wins its first lung cancer approval with a selective ROS1 inhibitor, Lilly's triple agonist retatrutide delivers up to 22.6 per cent weight loss in two pivotal trials, and the MHRA clears what it calls the world's first lower-carbon...

read more
Clinical Trials Roundup | 24 July 2026

Clinical Trials Roundup | 24 July 2026

Merck's enlicitide receives FDA approval as the first oral PCSK9 inhibitor for adults with hypercholesterolaemia, GSK's zidesamtinib earns FDA approval as a next-generation ROS1 selective inhibitor for previously treated non-small cell lung cancer, GSK's camlipixant...

read more
The False Economy of Returning to Manual PGD Processes

The False Economy of Returning to Manual PGD Processes

Across healthcare, financial pressure is forcing difficult decisions. Pharmacy teams are being asked to do more with less. Service expansion, dealing with NHS patients, workforce shortages remain acute, and every investment is being scrutinised. In this environment,...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Compliant on Paper, Exposed in Practice

Compliant on Paper, Exposed in Practice

A pharmaceutical manufacturer completes a technology transfer. The validation protocols have been approved. Training records are complete, documentation has been reviewed, and every required signature has been collected. The project passes its milestones and moves...

read more
From Reactive Reviews to Predictive Regulatory Intelligence

From Reactive Reviews to Predictive Regulatory Intelligence

Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....

read more
The Patient as Healthcare’s Systems Integrator

The Patient as Healthcare’s Systems Integrator

Healthcare has undergone a remarkable digital transformation over the past two decades. Electronic health records, electronic prescribing, patient portals, telemedicine, artificial intelligence, and remote monitoring have fundamentally changed how healthcare is...

read more
Weekly News Roundup | 20 July 2026

Weekly News Roundup | 20 July 2026

Life science news 20 July 2026: the FDA approves the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly makes the largest psychedelics deal in Big Pharma history, and a first-in-class breast cancer therapy wins regulatory clearance in a landmark week for...

read more
NAMs and Animal Testing: Separating Progress From Hype

NAMs and Animal Testing: Separating Progress From Hype

If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...

read more
Clinical Trials Roundup | 17 July 2026

Clinical Trials Roundup | 17 July 2026

Celcuity's gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen's diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer's disease, Novo Nordisk's...

read more

Further News

Vivan Therapeutics and Ad Atomica Announce Discovery Collaboration

Partnership pairs Vivan's genotype resolved cancer screening data with Ad Atomica's AI driven molecule design platform LONDON, UK, 16 September 2026: Vivan Therapeutics and Ad Atomica today announced a discovery collaboration. Vivan tests thousands of drugs and drug...

Azetukalner NDA Filed as Xenon Pauses Depression Trials

Xenon Pharmaceuticals submitted the azetukalner NDA to the US Food and Drug Administration on 17 September 2026. The filing covers focal seizures in epilepsy. The same announcement disclosed a voluntary pause on new enrolment in the company’s depression studies. Xenon...

Metal Medical Device Quality Control: Why Dimensions Are Not Enough

A correct dimension does not guarantee a safe device Metal device quality control should translate clinical and engineering risks into measurable attributes. A machined component can match its drawing, look clean and pass inspection while still carrying a material,...

Healthcare Innovation Is Not Always About Something New

Healthcare innovation is often associated with something new. A new technology. A new platform. A new device. A new digital service. But healthcare organizations do not always need to add something new to improve care. Sometimes, they need to change something that is...

Clinical Trials Roundup | 18 Sept 2026

Definium Therapeutics’ DT120 meets its primary endpoint in the Phase 3 Panorama study in generalised anxiety disorder, AstraZeneca’s camizestrant misses its primary endpoint in the Phase III SERENA-4 study in first-line breast cancer, Vera Therapeutics’ atacicept cuts...

Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

Vera Therapeutics has put a two-year kidney function dataset behind its bid for IgAN full approval. On 15 September 2026, the company reported the final efficacy analysis of the Phase 3 ORIGIN 3 trial. The trial tested Trutakna (atacicept-vymj) in adults with primary...

Digital Health and the Reordering of Life Sciences Commercialization

It’s been an extraordinary two years for anyone working in pharma commercialization, with the macro environment shifting meaningfully under the feet of all those sitting on the commercial side of pharma or building in digital health with pharma partnership...

From Data to Decisions: The Next Frontier in Diabetic Foot Care

If you are not aware of the statistics on diabetic limb loss, they deserve your attention.  Prevention is an absolute necessity.  We call this diabetic foot care, and the way podiatrists utilize these opportunities is moving into a more data-rich era. Remote...

Expedited IND Pilot Opens as UK Fast Track Bars First-in-Human

The FDA opened applications for its expedited IND pilot on 15 September 2026. Its criteria favour US trials, while the MHRA 14-day Phase 1 route excludes first-in-human studies.

    Why Pharmaceutical Quality Cannot Be Tested Into a Product

    In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...

    Fifty Patients, No Registry: MVA Research Meets in London

    Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...

    Semaglutide Patent Expiry: What Generics Did to Prices

    The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.